Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Conference Coverage

Conference Coverage
Adverse Event-Related Health Care Utilization and Cost Among Patients with HR+/HER2- Metastatic Breast Cancer
12/06/2023

Edited by Brandon Twyford

Edited by Brandon Twyford
Research presented at SABCS 2023 examines the economic impact of treating HR+/HER2- metastatic breast cancer, revealing that costs related to adverse events in patients undergoing late-line chemotherapy treatments are significant and...
Research presented at SABCS 2023 examines the economic impact of treating HR+/HER2- metastatic breast cancer, revealing that costs related to adverse events in patients undergoing late-line chemotherapy treatments are significant and...
Research presented at SABCS 2023...
12/06/2023
Journal of Clinical Pathways

Advertisement

News
Comparing Sacituzumab Govitecan and Physician’s Choice Treatment in HR+/HER2- Metastatic Breast Cancer: TROPiCS-02 Phase 3 Study Analysis
12/06/2023

Edited by: Grace Taylor

Edited by: Grace Taylor
Aditya Bardia, MD, and colleagues presented their findings from the TROPiCS-02 phase 3 clinical study, which compared the efficacy of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, and treatment of physician’s choice in...
Aditya Bardia, MD, and colleagues presented their findings from the TROPiCS-02 phase 3 clinical study, which compared the efficacy of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, and treatment of physician’s choice in...
Aditya Bardia, MD, and...
12/06/2023
Journal of Clinical Pathways
Conference Coverage
Study Reveals Insights into Cost-Effectiveness of Multigene Assays in Early-Stage Breast Cancer Treatment
12/06/2023

Edited by Brandon Twyford

Edited by Brandon Twyford
A recent study presented at the 2023 ASH Annual Meeting & Exposition compared the cost-effectiveness of four multigene assays used in early-stage breast cancer treatment, and revealed which was the most beneficial for cost savings and...
A recent study presented at the 2023 ASH Annual Meeting & Exposition compared the cost-effectiveness of four multigene assays used in early-stage breast cancer treatment, and revealed which was the most beneficial for cost savings and...
A recent study presented at the...
12/06/2023
Journal of Clinical Pathways
Ronald Barkley Headshot
Videos
Players and Disruptors in Health Care Industry Consolidation
12/05/2023

Featuring Ronald Barkley, MS, JD

Featuring Ronald Barkley, MS, JD ...
Ronald Barkley, MS, JD, Cancer Center Business Development Group, provides an overview of the current consolidation of the health care industry and the major players and disruptors leading this transformation.
Ronald Barkley, MS, JD, Cancer Center Business Development Group, provides an overview of the current consolidation of the health care industry and the major players and disruptors leading this transformation.
Ronald Barkley, MS, JD, Cancer...
12/05/2023
Cancer Care Business Exchange

Advertisement

News
Disparities in Palliative Care Access Highlighted in Nationwide Study of Deceased Lymphoma Patients
12/04/2023

Edited by Brandon Twyford

Edited by Brandon Twyford
Nationwide study reveals that deceased lymphoma patients receiving palliative care experience significantly lower total charges but no significant impact on adjusted length of stay. The research also highlights disparities in access, with...
Nationwide study reveals that deceased lymphoma patients receiving palliative care experience significantly lower total charges but no significant impact on adjusted length of stay. The research also highlights disparities in access, with...
Nationwide study reveals that...
12/04/2023
Journal of Clinical Pathways
News
Zanubrutinib Shows Superior Long-Term Outcomes vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/04/2023

Edited by Emry Lloyd

Edited by Emry Lloyd
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and...
12/04/2023
Journal of Clinical Pathways
News
Evaluation of First-Line Treatment Outcomes in Elderly Patients with Diffuse Large B-Cell Lymphoma
12/04/2023

Edited by Grace Taylor

Edited by Grace Taylor
Steven Bair, MD, and colleagues evaluated long-term outcomes across different first-line treatment regimens for elderly patients with DLBCL, including standard dose R-CHOP, reduced dose R-CHOP, and non-anthracycline alternative regimens.
Steven Bair, MD, and colleagues evaluated long-term outcomes across different first-line treatment regimens for elderly patients with DLBCL, including standard dose R-CHOP, reduced dose R-CHOP, and non-anthracycline alternative regimens.
Steven Bair, MD, and colleagues...
12/04/2023
Journal of Clinical Pathways

Advertisement

News
Comparative Study of Nemtabrutinib and Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
12/04/2023

Edited by Emry Lloyd

Edited by Emry Lloyd
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will...
12/04/2023
Journal of Clinical Pathways
Conference Coverage
Trends in the Use of Bruton Tyrosine Kinase Inhibitors and B-cell 2 Inhibitors for Treating CLL in Community Oncology Settings
11/29/2023

Edited by Grace Taylor

Edited by Grace Taylor
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and...
11/29/2023
Journal of Clinical Pathways
Todd Schonherz, American Oncology Network
Videos
Healthcare Industry Consolidation And What This Means For Community Oncology Practices
11/21/2023

Featuring Todd Schonherz

Featuring Todd Schonherz
Todd Schonherz, CEO of American Oncology Network, details his session on the impact that industry consolidation has had on community oncology practices at CPC+CBEx 2023.
Todd Schonherz, CEO of American Oncology Network, details his session on the impact that industry consolidation has had on community oncology practices at CPC+CBEx 2023.
Todd Schonherz, CEO of American...
11/21/2023
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use